A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants

Inclusion Criteria: * Have signed an informed consent document * Body mass index between 18 and 30 kg/m2, with body weight greater than or equal to 50 kg at screening * Must agree to use an adequate contraception method (eg, vasectomy, double-barrier, partner using effective contraception) and to not donate sperm from the study drug administration until Day 76 * Blood pressure between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic at screening * Non-smoker or participant who smokes no more than 10 cigarettes, or 2 cigars, or 2 pipes of tobacco per day for at least 6 months before the study drug administration Exclusion Criteria: * History of or current clinically significant medical illness determined by the investigators including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, and coagulation disorders * Clinically significant abnormal values for hematology, clinical chemistry or urinalysis * Clinically significant abnormal physical examination, vital signs or 12-lead electrocardiogram * A diagnosis of influenza infection or any constellation of clinical symptoms consistent with influenza infection within 14 days before the study drug administration is scheduled * Participants with a fever of over 37.5°C on Day -1 or at predose